Sugi Predict

Sugi Predict / Compounds / SCHEMBL1678172

SCHEMBL1678172

SCHEMBL1678172

CCCCCN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GGPS1 O95749 3/20 0.46
▸ LMNA P02545 3/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TOP1 P11387 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39
▸ S1PR2 O95136 1/20 0.37
▸ S1PR1 P21453 1/20 0.37
▸ S1PR3 Q99500 1/20 0.37
▸ S1PR5 Q9H228 1/20 0.37
▸ DNM1 Q05193 2/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ SPHK1 Q9NYA1 1/20 0.35
▸ GMNN O75496 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ THPO P40225 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15590764 1.00 GGPS1 (0.46) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL4754900 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL8640646 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL9813074 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL13169239 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL23016843 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL12258773 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL789161 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL13169240 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1
SCHEMBL17817249 0.98 GGPS1 (0.49) GGPS1LMNAL3MBTL1TOP1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230093189-A1 CLEANING COMPOSITIONS COMPRISING COPOLYMERS AND THEIR USE CLARIANT INTERNATIONAL LTD. (CH) 2023-03-23 — — US claimed
EP-4134422-A1 (CO)POLYMERS AND THEIR USE IN CLEANING COMPOSITIONS Clariant International Ltd (CH) 2023-02-15 — — EP claimed
EP-4107241-A1 CLEANING COMPOSITIONS COMPRISING COPOLYMERS AND THEIR USE Clariant International Ltd (CH) 2022-12-28 — — EP claimed
CN-115400079-A Drug-loaded fatty acid nanoemulsion and preparation method and application thereof 太阳雨林（厦门）生物医药有限公司 2022-11-29 — — CN claimed
CN-114788872-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2022-07-26 — — CN claimed
EP-2256497-B1 METHOD FOR QUANTIFICATION OF SOLUBLE LR11 SEKISUI MEDICAL CO LTD (JP) 2016-07-06 — — EP claimed
US-9261443-B2 Method for quantification of soluble LR 11 SEKISUI MEDICAL CO., LTD. (JP) 2016-02-16 — — US claimed
US-20130302826-A1 METHOD FOR QUANTIFICATION OF SOLUBLE LR 11 SEKISUI MEDICAL CO LTD (US) 2013-11-14 — — US claimed
EP-2566444-A2 FOAMING COSMETIC COMPOSITION CONTAINING ELLAGIC ACID OR ONE OF THE SALTS THEREOF AND AN ESSENTIAL OIL L'Oréal (FR) 2013-03-13 — — EP claimed
WO-2011138450-A2 FOAMING COSMETIC COMPOSITION CONTAINING ELLAGIC ACID OR ONE OF THE SALTS THEREOF AND AN ESSENTIAL OIL L'OREAL (FR) 2011-11-10 — — WO claimed
US-20110091993-A1 METHOD FOR QUANTIFICATION OF SOLUBLE LR11 SEKISUI MEDICAL CO., LTD. (JP) 2011-04-21 — — US claimed
EP-2256497-A1 METHOD FOR QUANTIFICATION OF SOLUBLE LR11 Sekisui Medical Co., Ltd. (JP) 2010-12-01 — — EP claimed
CN-1359288-A Improved method of transport across an adaptable semi-permeable barrier IDEA AG (DE) 2002-07-17 — — CN claimed
EP-0900181-B1 BRANCHED SURFACTANT MANUFACTURE PROCTER & GAMBLE (US) 2002-07-10 — — EP claimed
US-20020028976-A1 Branched surfactant manufacture Cook, C. 2002-03-07 — — US claimed
US-6320080-B2 DIMERIZING ALPHA OLEFINS, ISOMERIZING, REACTING WITH CARBON MONOXIDE AND HYDROGEN UNDER OXO CONDITIONS USING COBALT-CARBONYL-PHOSPHINE CATALYST, RECOVERING BRANCHED ALCOHOLS, OXIDIZING, RECOVERING BRANCHED ALKYL CARBOXYLATES THE PROCTER & GAMBLE COMPANY 2001-11-20 — — US claimed
US-20010034461-A1 BRANCHED SURFACTANT MANUFACTURE PROCTER & GAMBLE COMPANY, THE 2001-10-25 — — US claimed
EP-0796615-B1 Cleaning cosmetic composition containing an oxyalkylated silicon OREAL (FR) 2001-01-24 — — EP claimed
EP-0900181-A1 BRANCHED SURFACTANT MANUFACTURE THE PROCTER & GAMBLE COMPANY (US) 1999-03-10 — — EP claimed
WO-1997038957-A1 BRANCHED SURFACTANT MANUFACTURE THE PROCTER & GAMBLE COMPANY (US) 1997-10-23 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028976-A1 Branched surfactant manufacture SPTSSB, OSBP, EBP GGPS1 91/4885LMNA 2308/4885L3MBTL1 1109/4885
US-20010034461-A1 BRANCHED SURFACTANT MANUFACTURE SPTSSB, OSBP, EBP GGPS1 91/4885LMNA 2308/4885L3MBTL1 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.